Promoter methylation status of the FHIT gene and Fhit expression: Association with HER2/neu status in breast cancer patients

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2270-2278

  Jeong, Young Ju ^a   Jeong, Hye Yeon ^a   Lee, Sang Min ^a   Bong, Jin Gu ^a   Park, Sung Hwan ^a   Oh, Hoon Kyu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Breast cancer; Epigenetics; Fragile histidine triad; Human epidermal growth factor receptor 2; Methylation

Indexed keywords

BISULFITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; FEMALE; FHIT GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; TUMOR VOLUME;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2;

EID: 84885049240     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2668     Document Type: Article

References (38)

1. Dworkin AM, Huang TH and Toland AE: Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 19: 165-171, 2009.
2. Hinshelwood RA and Clark SJ: Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med 86: 1315-1328, 2008.
3. Widschwendter M and Jones PA: DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482, 2002.
4. Pogribny IP and Beland FA: DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mil Life Sci 66: 2249-2261, 2009.
5. Balch C, Montgomery JS, Paik HI, et al: New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci 10: 1897-1931, 2005.
6. Wali A: FHIT: Doubts are clear now. Sci World J 10: 1142-1151, 2010.
7. Ingvarsson S: FHIT alterations in breast cancer. Semin Cancer Biol 11: 361-366, 2001.
8. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG and Agnarsson BA: Alterations of the FHIT gene in breast cancer: association with tumour progression and patient survival. Cancer Detect Prev 25: 292-298, 2001.
9. Ahmadian M, Wistuba II, Fong KM, et al: Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57: 3664-3668, 1997.
10. Negrini M, Monaco G, Vorchovsky I, et al: The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173-3179, 1996.
11. Zöchbauer-Müller S, Fong KM, Maitra A, et al: 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61: 3581-3585, 2001.
12. Hayashi S, Tanimoto K, Hajiro-Nakanishi K, et al: Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 57: 1981-1985, 1997.
13. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, et al: Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 59: 2682-2689, 1999.
14. Gatalica Z, Lele SM, Rampy BA and Norris BA: The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 88: 1378-1383, 2000.
15. Naqvi RA, Hussain A, Raish M, et al: Specific 5' CpG island methylation signatures of FHIT and p16 genes and their potential diagnostic relevance in Indian breast cancer patients. DNA Cell Biol 27: 517-525, 2008.
16. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61: 8659-8663, 2001.
17. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8: 514-519, 2002.
18. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M and Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7: 584-589, 2001.
19. Kim H, Kwon YM, Kim JS, et al: Tumor-specific methylation in bronchial lavage for early detection on non-small cell lung cancer. J Clin Oncol 22: 2363-2370, 2004.
20. Raish M, Dhillon VS, Ahmad A, et al: Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Trans Oncol 2: 264-270, 2009.
21. Syeed N, Husain SA, Sameer AS, Chowdhri NA and Siddiqi MA: Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir. Mutation Res 707: 1-8, 2011.
22. Yang Q, Nakamura M, Nakamura Y, et al: Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 8: 2890-2893, 2002.
23. Fiegl H, Millinger S, Goebel G, et al: Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66: 29-33, 2006.
24. Bianchi F, Magnifico A, Olgiati C, et al: FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci USA 103: 18981-18986, 2006.
25. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
26. Menard S, Tagliabue E, Campiglio M and Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182: 150-162, 2000.
27. Pekarsky Y, Garrison PN, Palamarchuk A, et al: Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101: 3775-3779, 2004.
28. Campan M, Weisenberger DJ and Laird PW: DNA methylation profiles of female steroid hormone-driven human malignancies. Curr Top Microbiol Immunol 310: 141-178, 2006.
29. Bianchi F, Tagliabue E, Ménard S and Campiglio M: Fhit expression protects against HER2-driven breast tumor development. Cell Cycle 6: 643-646, 2007.
30. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S and Croce CM: FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59: 3866-3869, 1999.
31. Yang Q, Yoshimura G, Suzuma T, et al: Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 7: 3869-3873, 2001.
32. Arun B, Kilic G, Yen C, et al: Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14: 1681-1685, 2005.
33. Key TJ and Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24: 29-43, 1988.
34. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
35. Creighton CJ, Kent Osborne C, van de Vijver MJ, et al: Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114: 287-299, 2009.
36. Li L, Lee KM, Ha W, et al: Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet 19: 4273-4277, 2010.
37. Widschwendter M, Siegmund KD, Muller HM, et al: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64: 3807-3813, 2004.
38. Tost J and Gut IG: Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. Methods Mol Biol 373: 89-102, 2007.